@article{3089714,
    title = "Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer",
    author = "Petraki, C. and Dubinski, W. and Scorilas, A. and Saleh, C. and Pasic, M.D. and Komborozos, V. and Khalil, B. and Gabril, M.Y. and Streutker, C. and Diamandis, E.P. and Yousef, G.M.",
    journal = "PATHOLOGY RESEARCH AND PRACTICE",
    year = "2012",
    volume = "208",
    number = "2",
    pages = "104-108",
    issn = "0344-0338",
    doi = "10.1016/j.prp.2011.12.010",
    keywords = "kallikrein 6, adult;  aged;  article;  cancer staging;  clinical feature;  colon mucosa;  colorectal cancer;  controlled study;  correlation analysis;  disease course;  disease free survival;  female;  histopathology;  human;  human tissue;  immunohistochemistry;  liver metastasis;  lymph node metastasis;  major clinical study;  male;  overall survival;  prediction;  prognosis;  protein expression;  scoring system, Adult;  Aged;  Aged, 80 and over;  Carcinoma;  Chi-Square Distribution;  Colorectal Neoplasms;  Disease-Free Survival;  Female;  Greece;  Humans;  Immunohistochemistry;  Kallikreins;  Kaplan-Meier Estimate;  Liver Neoplasms;  Lymphatic Metastasis;  Male;  Middle Aged;  Neoplasm Staging;  Prognosis;  Proportional Hazards Models;  Risk Assessment;  Risk Factors;  Time Factors;  Tumor Markers, Biological",
    abstract = "The prognosis of patients with colorectal cancer (CRC) is assessed through conventional clinicopathological parameters, which are not always accurate. Members of the human kallikrein-related peptidases gene family represent potential cancer biomarkers. The aim of this study was to investigate the expression of human tissue kallikrein-related peptidase 6 (KLK6) by immunohistochemistry in CRC to correlate this expression with various histopathological and clinical variables, and to evaluate its significance as a predictor of disease outcome. KLK6 expression was evaluated by immunohistochemistry and an expression score was calculated for each case. In CRC, KLK6 expression was decreased compared to normal colonic mucosa. A statistically significant, positive association was observed between KLK6 and tumor stage (p=0.036), lymph node metastases (p=0.030), and liver metastases (p=0.025). Univariate analysis showed that KLK6 expression and stage had statistically significant correlation with disease-free survival (p=0.045 and p<0.001, respectively) and overall survival (p=0.027 and p<0.001, respectively). Cox multivariate analysis showed that KLK6 expression was an independent predictor of unfavorable overall survival (p=0.041). Kaplan-Meier survival curves showed that KLK6-positive patients have statistically significant lower disease-free and overall survival. In conclusion, KLK6 immunostaining is an independent prognostic marker in patients with CRC. © 2012 Elsevier GmbH."
}